Xencor Inc (XNCR) Receives Average Rating of “Hold” from Analysts

Shares of Xencor Inc (NASDAQ:XNCR) have received an average rating of “Hold” from the nine research firms that are covering the firm, MarketBeat reports. Three analysts have rated the stock with a sell rating, two have given a hold rating and four have issued a buy rating on the company. The average 12 month price target among brokerages that have covered the stock in the last year is $30.80.

Several research firms recently weighed in on XNCR. BidaskClub upgraded shares of Xencor from a “strong sell” rating to a “sell” rating in a research note on Wednesday, January 24th. Zacks Investment Research restated a “sell” rating on shares of Xencor in a research note on Saturday, January 13th. Piper Jaffray Companies restated a “buy” rating and set a $35.00 price target on shares of Xencor in a research note on Sunday, November 12th. ValuEngine cut shares of Xencor from a “hold” rating to a “sell” rating in a research note on Monday, October 23rd. Finally, Canaccord Genuity set a $36.00 price target on shares of Xencor and gave the stock a “buy” rating in a research note on Monday, October 23rd.

In other news, major shareholder John S. Stafford III bought 9,215 shares of the business’s stock in a transaction dated Thursday, December 14th. The stock was bought at an average price of $20.76 per share, for a total transaction of $191,303.40. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, major shareholder John S. Stafford III bought 5,349 shares of the business’s stock in a transaction dated Friday, November 24th. The stock was purchased at an average price of $19.85 per share, with a total value of $106,177.65. The disclosure for this purchase can be found here. Insiders bought 36,153 shares of company stock valued at $731,583 in the last quarter. 4.03% of the stock is currently owned by corporate insiders.

Large investors have recently bought and sold shares of the company. Great West Life Assurance Co. Can raised its stake in shares of Xencor by 158.9% in the third quarter. Great West Life Assurance Co. Can now owns 6,526 shares of the biopharmaceutical company’s stock valued at $150,000 after acquiring an additional 4,005 shares during the last quarter. Legal & General Group Plc raised its stake in shares of Xencor by 4.5% in the second quarter. Legal & General Group Plc now owns 8,978 shares of the biopharmaceutical company’s stock valued at $189,000 after acquiring an additional 385 shares during the last quarter. Principal Financial Group Inc. bought a new position in shares of Xencor in the third quarter valued at approximately $201,000. UBS Asset Management Americas Inc. bought a new position in shares of Xencor in the fourth quarter valued at approximately $205,000. Finally, Citadel Advisors LLC bought a new position in shares of Xencor in the second quarter valued at approximately $224,000. Institutional investors own 77.50% of the company’s stock.

Shares of Xencor (NASDAQ XNCR) opened at $21.70 on Friday. Xencor has a one year low of $18.55 and a one year high of $28.64. The firm has a market cap of $1,020.00, a PE ratio of -21.49 and a beta of 1.97.

Xencor (NASDAQ:XNCR) last released its earnings results on Tuesday, November 7th. The biopharmaceutical company reported ($0.33) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.29) by ($0.04). Xencor had a negative net margin of 148.29% and a negative return on equity of 15.26%. equities analysts expect that Xencor will post -1.1 earnings per share for the current fiscal year.

ILLEGAL ACTIVITY WARNING: “Xencor Inc (XNCR) Receives Average Rating of “Hold” from Analysts” was originally posted by American Banking News and is the sole property of of American Banking News. If you are reading this piece of content on another website, it was illegally stolen and reposted in violation of US and international trademark & copyright legislation. The original version of this piece of content can be read at https://www.americanbankingnews.com/2018/02/10/xencor-inc-xncr-receives-average-rating-of-hold-from-analysts.html.

About Xencor

Xencor, Inc is a clinical-stage biopharmaceutical company. The Company is focused on discovering and developing engineered monoclonal antibodies to treat severe and life threatening diseases. It has developed two clinical-stage product candidates, using its Immune Inhibitor Fc platform: XmAb5871, which is in two Phase II trials and is being developed for autoimmune disease, and XmAb7195, which is in a Phase I trial and is being developed for asthma and allergic diseases.

Analyst Recommendations for Xencor (NASDAQ:XNCR)

Receive News & Ratings for Xencor Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Xencor and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply